VK2735 Updated Oct 24
The key near-term catalyst is Q3 2026 earnings on Oct 28, 2026, where management may provide Phase 3 timeline updates. The Phase 3 SUNRISE-1/2 trials were just initiated in Oct 2026, so topline data is likely 18-24+ months away. With the stock at ~$24.40 near 52-week lows and the mean analyst target at ~$95, the risk/reward hinges on whether Phase 3 data mirrors the strong Phase 2 results, but significant capital dilution (~$575M raise in Sept 2026) has already weighed on shares.
- VK2735 is a dual GLP-1/GIP receptor agonist (same mechanism as Eli Lilly's blockbuster tirzepatide) that has already demonstrated promising Phase 2 weight-loss data, supporting an oral Phase 3 program (SUNRISE-1 and SUNRISE-2) initiated in October 2026.
- Analyst consensus is overwhelmingly bullish: 23 Buy/Strong Buy ratings vs 3 Hold, zero Sells, with a mean price target of ~$95.05 against the current ~$24.40 stock price, implying roughly 290% upside.
- The company raised ~$575M in gross proceeds in Sept 2026 specifically to fund VK2735's Phase 3 development and potential commercialization, removing near-term financing risk.
- VK2735 enters a massive competitive market already dominated by Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Zepbound/Mounjaro/tirzepatide), which target the same dual GLP-1/GIP mechanism, VK2735 will need to show best-in-class data to carve out market share.
- The stock has fallen from $43.15 52-week high to $24.40 (near 52-week low) as of Oct 23, 2026, and a ~$575M capital raise via convertible notes and common stock in Sept 2026 has diluted existing shareholders significantly, with a $50.75/share note conversion price creating overhang.
- Short interest is high at roughly 20.62% of estimated shares outstanding as of Sept 30, 2026, and the bull/bear evidence scan shows a net bearish signal with 16+ institutional exits/trims and ~$5M in insider sales by the CEO and CFO in July 2026.